Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of 2,940-nm Fractional Ablative Erbium and Topical DNA Repair Enzymes on p53 Epidermal Expression After 3 Months: A Comparative Clinical Trial

NCT04277949 is registered in ClinicalTrials.gov with Moy-Fincher-Chipps Facial Plastics and Dermatology as lead sponsor.

NCT NCT04277949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04277949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of 2,940-nm Fractional Ablative Erbium and Topical DNA Repair Enzymes on p53 Epidermal Expression After 3 Months: A Comparative Clinical Trial
Lead sponsor
Moy-Fincher-Chipps Facial Plastics and Dermatology
Phase
Not applicable
Overall status
Unknown status
Start date
April 30, 2020
Completion date
August 31, 2020
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

p53 expression